Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Substantial late mortality risk persists after childhood BMT

Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

Key clinical point: Individuals undergoing allogeneic blood or marrow transplantation (BMT) in childhood require careful follow-up for many years because of a persistent elevated risk of premature death.

Major finding: Risk of premature death was increased 14.4-fold, compared with the general population (95% confidence interval, 12.8-16.1).

Study details: A retrospective cohort study including 1,388 individuals living 2 years or more after allogeneic BMT performed in childhood.

Disclosures: The study was supported in part by grants from the National Cancer Institute, the Leukemia Lymphoma Society, and the Swedish Childhood Cancer Foundation. Dr. Holmqvist and her coauthors reported no conflicts of interest.

Read article here.

Citation:

Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

This Week's Must Reads

Bortezomib looks promising in WM mutations, Sklavenitis-Pistofidis R et al. Blood. 2018 Oct 26. doi: 10.1182/blood-2018-07-863241

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Patient blood management in stem cell transplant, Jambhekar N et al. AABB 2018, Abstract PBM3-ST4-22

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.